Penalization Theory and Practice for Cox Models

Biomarker-based phase III clinical trial: Real-world experiences

Estimating effects of time-varying treatments: pitfalls and opportunities

Evaluating and addressing consistency of the evidence in a network metaanalysis

Recent developments in updating and extending risk prediction models, the European Randomized Study of Prostate Cancer Risk Calculator

From model building to validation and back: a plea for robustness

Using network meta-analysis for decision making

Joint longitudinal survival models for prediction of prostate cancer recurrence following radiotherapy

Adaptive designs for confirmatory clinical trials with treatment selection

Recent developments in updating and extending risk prediction models, the Prostate Cancer Prevention Trial Calculator

Gene signatures as treatment modifiers in clinical trial

Biomarker-based phase II trial designs

Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy

Causal search in high-dimensional settings

Assessing mediation through multiple pathways using natural effect models

The meta-analytic approach to validation of surrogate endpoints

TBD (on meta-regression)

Two folklores: ridge regression versus the lasso

Purposeful penalization of likelihood in small samples